Then, on July 31, the Health Resources and Services Administration (HRSA) announced the revised 340B Rebate Model Pilot Program. First up, CMS wants to update payment rates for drugs purchased under the 340B Drug Pricing Program to better reflect what hospitals pay for these medications. The agency cited a survey finding that hospitals pay for 340B drugs at an average cost significantly below the Average Sales Price (ASP), while Medicare payments have substantially exceeded 340B drug acquisition costs. Meanwhile, the revised 340B Rebate Model Pilot Program has already gone through its commenting period. Related:State drug price caps may harm patient access despite affordability goals